NASDAQ:LJPC - La Jolla Pharmaceutical Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.56 -0.19 (-2.81 %)
(As of 01/16/2019 04:00 PM ET)
Previous Close$6.75
Today's Range$6.40 - $6.8635
52-Week Range$5.01 - $41.36
Volume1.37 million shs
Average Volume1.56 million shs
Market Capitalization$164.22 million
P/E Ratio-1.21
Dividend YieldN/A
Beta1.72
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. The company is developing LJPC-401, a formulation of synthetic human hepcidin for the treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease, and myelodysplastic syndrome. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.

Receive LJPC News and Ratings via Email

Sign-up to receive the latest news and ratings for LJPC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LJPC
CUSIPN/A
Phone858-207-4264

Debt

Current Ratio8.92
Quick Ratio8.88

Price-To-Earnings

Sales & Book Value

Annual Sales$620,000.00
Price / Sales277.53
Price / Cash FlowN/A
Book Value$3.68 per share
Price / Book1.78

Profitability

Net Income$-114,800,000.00
Net MarginsN/A
Return on Assets-94.34%

Miscellaneous

Employees309
Market Cap$164.22 million
OptionableOptionable

La Jolla Pharmaceutical (NASDAQ:LJPC) Frequently Asked Questions

What is La Jolla Pharmaceutical's stock symbol?

La Jolla Pharmaceutical trades on the NASDAQ under the ticker symbol "LJPC."

How were La Jolla Pharmaceutical's earnings last quarter?

La Jolla Pharmaceutical (NASDAQ:LJPC) announced its quarterly earnings data on Wednesday, October, 24th. The biopharmaceutical company reported ($1.93) EPS for the quarter, topping the Zacks' consensus estimate of ($2.01) by $0.08. The biopharmaceutical company had revenue of $3.47 million for the quarter, compared to analyst estimates of $3.38 million. View La Jolla Pharmaceutical's Earnings History.

When is La Jolla Pharmaceutical's next earnings date?

La Jolla Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for La Jolla Pharmaceutical.

What price target have analysts set for LJPC?

5 equities research analysts have issued 1-year price targets for La Jolla Pharmaceutical's stock. Their forecasts range from $6.00 to $115.00. On average, they expect La Jolla Pharmaceutical's share price to reach $42.40 in the next year. This suggests a possible upside of 546.3% from the stock's current price. View Analyst Price Targets for La Jolla Pharmaceutical.

What is the consensus analysts' recommendation for La Jolla Pharmaceutical?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for La Jolla Pharmaceutical in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for La Jolla Pharmaceutical.

What are Wall Street analysts saying about La Jolla Pharmaceutical stock?

Here are some recent quotes from research analysts about La Jolla Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases. " (1/11/2019)
  • 2. HC Wainwright analysts commented, "We are reducing our price target to $25, from $48, due to lower Giapreza sales expectations partially offset by cost cutting expectations in R&D and SG&A. We base our $25 price target on a sum-of-the-parts analysis based on: (1) the P/E value of La Jolla’s current commercial business (Giapreza); (2) an NPV of its pipeline (LJPC-401); and (3) our estimated year- end fully diluted net cash of $4.03/share, which includes the capital raise earlier this year and the royalty agreement, to arrive at our price target. We value the current commercial business at $9.82 per share and the pipeline at $10.83 per share." (1/9/2019)

Has La Jolla Pharmaceutical been receiving favorable news coverage?

Media coverage about LJPC stock has trended somewhat negative on Wednesday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. La Jolla Pharmaceutical earned a news sentiment score of -1.2 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the next several days.

Who are some of La Jolla Pharmaceutical's key competitors?

Who are La Jolla Pharmaceutical's key executives?

La Jolla Pharmaceutical's management team includes the folowing people:
  • Dr. George F. Tidmarsh, Pres, CEO, Sec. & Director (Age 59)
  • Mr. Dennis M. Mulroy, Chief Financial Officer (Age 64)
  • Ms. Jennifer A. Carver, Chief Operating Officer (Age 65)
  • Mr. James M. Rolke, Chief Scientific Officer (Age 50)
  • Dr. Lakhmir S. Chawla, Chief Medical Officer (Age 48)

Who are La Jolla Pharmaceutical's major shareholders?

La Jolla Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Fox Run Management L.L.C. (0.04%). Company insiders that own La Jolla Pharmaceutical stock include Dennis Mulroy, George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Laura L Douglass, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Institutional Ownership Trends for La Jolla Pharmaceutical.

Which institutional investors are buying La Jolla Pharmaceutical stock?

LJPC stock was purchased by a variety of institutional investors in the last quarter, including Fox Run Management L.L.C.. Company insiders that have bought La Jolla Pharmaceutical stock in the last two years include Dennis Mulroy, George F Tidmarsh, James Rolke, Jennifer Carver, Kevin C Tang, Lakhmir S Chawla, Life Sciences Maste Perceptive and Perceptive Advisors Llc. View Insider Buying and Selling for La Jolla Pharmaceutical.

How do I buy shares of La Jolla Pharmaceutical?

Shares of LJPC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is La Jolla Pharmaceutical's stock price today?

One share of LJPC stock can currently be purchased for approximately $6.56.

How big of a company is La Jolla Pharmaceutical?

La Jolla Pharmaceutical has a market capitalization of $164.22 million and generates $620,000.00 in revenue each year. The biopharmaceutical company earns $-114,800,000.00 in net income (profit) each year or ($5.41) on an earnings per share basis. La Jolla Pharmaceutical employs 309 workers across the globe.

What is La Jolla Pharmaceutical's official website?

The official website for La Jolla Pharmaceutical is http://www.lajollapharmaceutical.com.

How can I contact La Jolla Pharmaceutical?

La Jolla Pharmaceutical's mailing address is 4550 TOWNE CENTRE COURT, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-207-4264 or via email at [email protected]


MarketBeat Community Rating for La Jolla Pharmaceutical (NASDAQ LJPC)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  277 (Vote Outperform)
Underperform Votes:  227 (Vote Underperform)
Total Votes:  504
MarketBeat's community ratings are surveys of what our community members think about La Jolla Pharmaceutical and other stocks. Vote "Outperform" if you believe LJPC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LJPC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/16/2019 by MarketBeat.com Staff

Featured Article: Index Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel